Financial Performance - Research and development expenses for Q3 2025 were $158,699, compared to $153,282 in Q3 2024, reflecting a slight increase [5]. - General and administrative expenses for Q3 2025 were $1.75 million, an increase of $1.2 million from $0.52 million in Q3 2024, primarily due to legal and advisory services related to the direct listing [5]. - The company reported a net loss of $1.90 million for Q3 2025, compared to a net loss of $666,442 in Q3 2024 [6]. - Total operating expenses for Q3 2025 were $1.91 million, compared to $672,992 in Q3 2024, indicating a significant increase [6]. - As of September 30, 2025, Turn Therapeutics had $3.11 million in cash and cash equivalents, up from $872,599 at the end of 2024 [7]. Corporate Developments - Turn Therapeutics began trading on NASDAQ under the ticker TTRX on October 8, 2025, allowing the company to secure funding from public markets [1]. - The company entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products, to leverage its PermaFusion® platform technology [3]. - The company appointed two new members to its Board of Directors, enhancing its leadership team with extensive experience in regulatory and clinical development [5]. Clinical Advancements - The clinical trial for the first topical IL-36/IL-31 inhibitor for eczema has commenced, building on thousands of prior uses of the formula [5]. - Turn Therapeutics is advancing late-stage clinical programs in eczema and onychomycosis, reflecting its commitment to developing best-in-class products [2].
Global Health Solutions(TTRX) - 2025 Q3 - Quarterly Results